Veozah Label Update: Boxed Warning for Hepatotoxicity Added
The FDA has updated the prescribing information for Veozah (fezolinetant) to include a boxed warning for hepatotoxicity, following reports of serious liver injuries. This oral neurokinin 3 receptor antagonist is used to manage menopause-related vasomotor symptoms, such as hot flashes. Healthcare providers are now required to evaluate hepatic function before treatment and monitor liver health regularly to ensure patient safety.
Montelukast (Singulair) Linked to Serious Mental Health Risks, Especially in Children
In a recent study, it has been discovered that the popular asthma and allergy drug montelukast, also known as Singulair, can potentially cause serious mental health risks, especially in children. Despite these alarming findings, the drug continues to be widely…